About this episode
In this Market Mondays Medium #6 clip, Rashad Bilal, Troy Millings, and Ian Dunlap dive deep into the volatile world of healthcare stocks and whether the sector is positioned for a rebound in 2025. The team breaks down why healthcare has struggled, from overseas pharmaceutical tariffs and lawsuits to the misconception that healthcare can match tech stock returns. With new tariffs on international pharmaceuticals and litigation like the Ozempic lawsuit shaking the industry, there’s plenty to consider before adding healthcare stocks to your portfolio. Ian Dunlap shares his take on the sector’s future, noting that expecting “tech-like returns” from healthcare was a major mistake. The discussion covers key American companies—including Eli Lilly, Johnson & Johnson, ABBV, UnitedHealth, Abbott, Merck, and Stryker—highlighting those with strong policy support and innovative biotech advances. Troy Millings points out the disruptive potential of AI in healthcare, emphasizing that upcoming breakthroughs and administration policy will play a significant role. The hosts unanimously stress the importance of focusing on top American healthcare companies, especially given the implications of domestic manufacturing and tariffs. They recommend using healthcare ETFs like XLV to monitor top allocations and add stability to your portfolio. For those wondering if healthcare belongs in their investment mix, the consensus is clear: exposure to healthcare is wise, especially if you stick with sector leaders. Ian narrows his top picks to Eli Lilly, ABBV, and Stryker. However, don’t expect dramatic 35-45% returns as you might with tech; healthcare provides steady, long-term opportunities rather than quick wins. Whether you’re a seasoned investor or new to the stock market, this clip provides actionable insights and a grounded outlook on what to expect from healthcare stocks in the coming year. If you’ve wondered about CVS, United Healthcare, or how U.S. healthcare spending compares globally, the crew covers that too—reminding us that, despite being one of the largest markets, the U.S. still lags in health outcomes. *Key Takeaways:* Healthcare sector’s challenges in 2024, including tariffs and lawsuits Realistic returns vs. tech sector expectations American healthcare companies to watch: Eli Lilly, ABBV, Stryker How AI and biotech innovation could accelerate sector growth The impact of U.S. policy and tariffs on investment choices Using healthcare ETFs (like XLV) for strategic exposure Why healthcare should (or shouldn’t) be part of your portfolio If you want honest, in-depth analysis of the healthcare market and a roadmap for making informed investment decisions in 2025, this is the clip you can’t miss. Like, subscribe, and let us know your thoughts on the future of healthcare stocks in the comments! #HealthcareStocks #MarketMondays #Investing #EliLilly #ABBV #Stryker #TechVsHealthcare #Tariffs #AIinHealthcare #StockMarketAnalysis #ETFs #PortfolioStrategy See omnystudio.com/listener for privacy information.